Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

Gill, Steven S., Patel, Nikunj K., Hotton, Gary R., O'Sullivan, Karen, McCarter, Renée, Bunnage, Martin, Brooks, David J., Svendsen, Clive N. +1 more·2003·Nature Medicine
DOI 10.1038/nm850

Cited by (1,000)

Items 401–500 of 1,000

  1. MPTP‐induced deficits in striatal synaptic plasticity are prevented by glial cell line‐derived neurotrophic factor expressed via an adeno‐associated viral vector
    Yuan‐Hao Chen, Brandon K. Harvey, Alexander F. Hoffman, Yun Wang, Yung Hsiao Chiang, Carl R. Lupica · 2007 · The FASEB Journal
  2. Launching invasive, first‐in‐human trials against Parkinson's disease: Ethical considerations
    Jonathan Kimmelman, Alex John London, Bernard M. Ravina, Tim Ramsay, Mark Bernstein, Alan Fine, Frank W. Stahnisch, Marina Elena Emborg · 2009 · Movement Disorders
  3. Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation
    Jiaming Mei, Chaoshi Niu · 2014 · Neurological Sciences
  4. Treatment of early Parkinson's disease
    Rajesh Pahwa, Kelly E. Lyons · 2014 · Current Opinion in Neurology
  5. Pharmacologically active microcarriers releasing glial cell line – derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats
    Valerie M. Tatard-Leitman, Laurence Sindji, Jennifer Branton, Anne Aubert‐Pouëssel, Jacqueline Colleau, Jean‐Pierre Benoît, Claudia N. Montero‐Menei · 2007 · Biomaterials
  6. Disease-modifying drugs and Parkinson's disease
    H. Allain, Danièle Bentué‐Ferrer, Yvette Akwa · 2007 · Progress in Neurobiology
  7. Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke
    Rawan M. Tarawneh, James E. Galvin · 2010 · Clinics in Geriatric Medicine
  8. Neurotrophic factors hold promise for the future of Parkinson’s disease treatment: is there a light at the end of the tunnel?
    Ava Nasrolahi, Javad Mahmoudi, Abolfazl Akbarzadeh, Mohammad Karimipour, Saeed Sadigh‐Eteghad, Roya Salehi, Mehdi Farhoudi · 2018 · Reviews in the Neurosciences
  9. MRI-Guided, Noninvasive Delivery of Magneto-Electric Drug Nanocarriers to the Brain in a Nonhuman Primate
    Ajeet Kumar Kaushik, Jose E Rodriguez, Daniel Rothen, Vinay Bhardwaj, Rahul Dev Jayant, Pradip M. Pattany, B Fuentes, Hitendra Singh Chand, Nagesh Kolishetti, Nazira El‐Hage et al. · 2019 · ACS Applied Bio Materials
  10. Intraputamenal Infusion of Exogenous Neurturin Protein Restores Motor and Dopaminergic Function in the Globus Pallidus of MPTP-Lesioned Rhesus Monkeys
    Richard Grondin, Z. Zhang, Yi Ai, F. Ding, Ashley Walton, Stewart P. Surgener, Greg A. Gerhardt, Don Marshall Gash · 2008 · Cell Transplantation
  11. Neurodegeneration and cell replacement
    Brandi K. Ormerod, Theo D. Palmer, Maeve A. Caldwell · 2007 · Philosophical Transactions of the Royal Society B Biological Sciences
  12. Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models
    Katherine E. Soderstrom, Jennifer A. O’Malley, Kathy Steece‐Collier, Jeffrey H. Kordower · 2006 · Cell Transplantation
  13. Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer
    Ashok Rajappa Asthagiri, Stuart Walbridge, John D. Heiss, Russell R. Lonser · 2011 · Journal of neurosurgery
  14. Safety of real-time convection-enhanced delivery of liposomes to primate brain: A long-term retrospective
    Michal Tadeusz Krauze, Scott R. VandenBerg, Yoji Yamashita, Ryuta Saito, John Forsayeth, Charles O. Noble, John B. Park, Krystof S. Bankiewicz · 2007 · Experimental Neurology
  15. Spheramine for Treatment of Parkinson’s Disease
    Natividad P. Stover, Ray L. Watts · 2008 · Neurotherapeutics
  16. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor
    Mahmoud M. Iravani, Mona Sadeghian, Clement C.M. Leung, Peter G. Jenner, Sarah Rose · 2012 · Neuroscience Letters
  17. GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance
    Mihwa Kim, Dae Joon Kim · 2018 · International Journal of Molecular Sciences
  18. The Future of GDNF in Parkinson's Disease
    Fredric P. Manfredsson, Nicole K. Polinski, Thyagarajan Subramanian, Nicholas M. Boulis, Dustin R. Wakeman, Ronald J. Mandel · 2020 · Frontiers in Aging Neuroscience
  19. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector
    Abdelwahed Chtarto, X. Yang, Olivier Bockstael, C. Melas, David L Blum, Enni Lehtonen, Laurence Abeloos, J.-M. Jaspar, Marc Levivier, Jacques Brotchi et al. · 2007 · Experimental Neurology
  20. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes
    Natalija Popović, Matthew Maingay, Deniz Kirik, Patrik Brundin · 2005 · Experimental Neurology
  21. Cell transplantation and gene therapy in Parkinson's disease.
    D. R. Wakeman, Hemraj B. Dodiya, J. Kordower · 2011 · The Mount Sinai journal of medicine, New York
  22. Trophic factors for Parkinson's disease: Where are we and where do we go from here?
    Gesine Paul, Aideen M. Sullivan · 2018 · European Journal of Neuroscience
  23. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
    Isobel J. Sleeman, Eugene L. Boshoff, Susan Duty · 2012 · Neuropharmacology
  24. Selective Activation of Cells by Piezoelectric Molybdenum Disulfide Nanosheets with Focused Ultrasound
    Ching‐Hsiang Fan, Hong‐Chieh Tsai, Yi-Sheng Tsai, Hsien‐Chu Wang, Yu‐Chun Lin, Po‐Han Chiang, Nan Wu, Min-Hwa Chou, Yi-Ju Ho, Zong‐Hong Lin et al. · 2023 · ACS Nano
  25. Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics
    Dali Yin, Robert Mark Richardson, Massimo S. Fiandaca, John Bringas, John Forsayeth, Mitchel Stuart Berger, Krystof S. Bankiewicz · 2010 · Journal of neurosurgery
  26. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres
    Elisa Garbayo, Eduardo Ansorena, José Luis Lanciego, Marta Aymerich, María J. Blanco‐Prieto · 2008 · European Journal of Pharmaceutics and Biopharmaceutics
  27. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
    Makoto Naoi, Wakako Maruyama, Keiko Inaba-Hasegawa · 2013 · Expert Review of Neurotherapeutics
  28. Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials
    Frederick L. Hitti, Andrew I. Yang, Pedro Gonzalez‐Alegre, Gordon H. Baltuch · 2019 · Parkinsonism & Related Disorders
  29. Death Receptors and Caspases But Not Mitochondria Are Activated in the GDNF- or BDNF-Deprived Dopaminergic Neurons
    Li-Ying Yu, Märt Saarma, Urmas Arumäe · 2008 · Journal of Neuroscience
  30. LY503430: Pharmacology, Pharmacokinetics, and Effects in Rodent Models of Parkinson's Disease
    Michael J. O’Neill, Tracey K. Murray, Michael P. Clay, Terry D. Lindstrom, Charles R. Yang, Eric S. Nisenbaum · 2006 · CNS Drug Reviews
  31. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography
    Wing Lok Au, John R. Adams, André R. Troiano, A. Jon Stoessl · 2004 · Molecular Brain Research
  32. Prevention of onset of Parkinson’s disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson’s disease
    Hiromi Koike, A Ishida, Munehisa Shimamura, S Mizuno, Takashi Nakamura, Toshio Ogihara, Yasufumi Kaneda, Ryuichi Morishita · 2006 · Gene Therapy
  33. Cell-Replacement and Gene-Therapy Strategies for Parkinson‘s and Alzheimer‘s Disease
    Joanna A. Korecka, Joost Verhaagen, Elly M. Hol · 2007 · Regenerative Medicine
  34. The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
    Cristina Lanni, Serena Stanga, Marco Racchi, Stefano M. Govoni · 2010 · Current Pharmaceutical Design
  35. Available and emerging treatments for Parkinson’s disease: a review
    Mark A. Stacy, Patrick Hickey, Mark A. Stacy · 2011 · Drug Design Development and Therapy
  36. Parkinson's disease: 10 years of progress, 1997–2007
    Stanley Fahn · 2010 · Movement Disorders
  37. GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution
    Richard Grondin, O. Meagan Littrell, Zhiming Zhang, Yi Ai, Peter F. Huettl, François Pomerleau, Jorge E. Quintero, Anders H. Andersen, Mallory J. Stenslik, Luke H. Bradley et al. · 2018 · Neuropharmacology
  38. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons
    Marjo Piltonen, Maxim M. Bespalov, Dagmar Ervasti, Tero Matilainen, Yulia A. Sidorova, Heikki Rauvala, Märt Saarma, Pekka T. Männistö · 2009 · Experimental Neurology
  39. Neuronal expression of the transcription factor Gli1 using the Tα1 α-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease
    D Suwelack, Andres Hurtado‐Lorenzo, E Millan, Valeria Gonzalez‐Nicolini, Kolja Wawrowsky, Pedro Ricardo Lowenstein, Maria Graciela Castro · 2004 · Gene Therapy
  40. Anatomical basis of glial cell line‐derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat
    Tinmarla Frances Oo, Vincent Ries, Jinwhan Cho, Nikolai G. Kholodilov, Robert E. Burke · 2005 · The Journal of Comparative Neurology
  41. Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease
    Elisa Garbayo, Eduardo Ansorena, José Luis Lanciego, María J. Blanco‐Prieto, María S. Aymerich · 2011 · Movement Disorders
  42. Dopamine Neuron Stimulating Actions of a GDNF Propeptide
    Luke H. Bradley, Josh Fuqua, April R. Hatcher, Jadwiga T. Turchan-Cholewo, Yi Ai, Kristen A. Kelps, John D. Glass, Xiuquan He, Zhiming Zhang, Richard Grondin et al. · 2010 · PLoS ONE
  43. Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease
    Pia Runeberg‐Roos, Elisa Piccinini, Anna‐Maija Penttinen, Kärt Mätlik, Hanna Heikkinen, Satu Kuure, Maxim M. Bespalov, Johan Peränen, Enrique Garea‐Rodríguez, Eberhard Fuchs et al. · 2016 · Neurobiology of Disease
  44. Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery
    William M. Pardridge, Rubén J. Boado · 2009 · Pharmaceutical Research
  45. The potential of GDNF as a treatment for Parkinson's disease
    Carrie B. Hurelbrink, Roger A. Barker · 2003 · Experimental Neurology
  46. Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
    Fredric P. Manfredsson, Michael S. Okun, Ronald J. Mandel · 2009 · Current Gene Therapy
  47. A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease
    Barry J. Snow, Eoin Mulroy, Arnold P. L. Bok, Mark Simpson, Andrew Smith, Kenneth Taylor, Michelle Marie Lockhart, BB Janice Lam, CHRISTOPHER M. A. FRAMPTON, Patrick M. Schweder et al. · 2018 · Parkinsonism & Related Disorders
  48. Glial cell line-derived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury
    Haikun Shi, Daniel Patschan, Gunnar P.H. Dietz, Mathias Bähr, Matthew D. Plotkin, Michael S. Goligorsky · 2007 · American Journal of Physiology-Renal Physiology
  49. Signalling mechanisms underlying development and maintenance of dopamine neurons
    Jaan‐Olle Andressoo, Märt Saarma · 2008 · Current Opinion in Neurobiology
  50. Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle
    Naomi P. Visanji, Michael J. O’Neill, Susan Duty · 2006 · Neuropharmacology
  51. Regulation of Brain-Derived Neurotrophic Factor (BDNF) and Cerebral Dopamine Neurotrophic Factor (CDNF) by Anti-Parkinsonian Drug Therapy In Vivo
    Tobias Gyárfás, Juha E. A. Knuuttila, Päivi Lindholm, Tomi Rantamäki, Eero Ċastrén · 2009 · Cellular and Molecular Neurobiology
  52. Transplantation of glial cell line‐derived neurotrophic factor‐expressing cells into the striatum and nucleus accumbens attenuates acquisition of cocaine self‐administration in rats
    T. Green-Sadan, Noa Kinor, Ilana Roth‐Deri, Revital Geffen, Cheryl J. Schindler, Gal Yadid · 2003 · European Journal of Neuroscience
  53. Therapeutic strategies in multiple system atrophy
    Gregor Karl Wenning, Felix Geser, Werner H Poewe · 2005 · Movement Disorders
  54. An update on the treatment of Parkinson's disease.
    Joseph J. Jankovic · 2006 · PubMed
  55. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
    N. G. Rainov, Yoshio Tsuboi, Pierre Krolak‐Salmon, Alain Vighetto, Katsumi Doh‐ura · 2007 · Expert Opinion on Biological Therapy
  56. Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
    Kerri‐Lee Wallom, María E. Fernández‐Suárez, David A. Priestman, Daniëlle te Vruchte, Mylene Huebecker, Penelope J. Hallett, Ole Isacson A, Frances M. Platt · 2021 · Glycoconjugate Journal
  57. Parkinsons Disease: Genetics and Beyond
    N. Inamdar, D.K. Arulmozhi, Anurag Tandon, Subhash Laxmanrao Bodhankar · 2007 · Current Neuropharmacology
  58. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)
    Christopher D. Herzog, Lamar Brown, Brian R. Kruegel, Alistair Wilson, Malú G. Tansey, Fred H. Gage, Eugene M. Johnson, Raymond T. Bartus · 2013 · Neurobiology of Disease
  59. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects
    Gretchen M. Thomsen, Mor R. Alkaslasi, Jean‐Philippe Vit, G Lawless, Marlesa I. Godoy, Genevíève Gowing, O Shelest, Clive Niels Svendsen · 2017 · Gene Therapy
  60. Long‐term functional restoration by neural progenitor cell transplantation in rat model of cognitive dysfunction: co‐transplantation with olfactory ensheathing cells for neurotrophic factor support
    N. Srivastava, Kavita Seth, Vinay Kumar Khanna, Reyaz W. Ansari, A.K. Agrawal · 2008 · International Journal of Developmental Neuroscience
  61. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease
    Weiguo Liu, Guoqiang Lü, Biao Li, Shengdi Chen · 2006 · Parkinsonism & Related Disorders
  62. Neural Stem Cell Therapy in the Aging Brain: Pitfalls and Possibilities
    Tobi L. Limke, Mahendra S. Rao · 2003 · Stem Cells and Development
  63. Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease
    Stina Friling, Maria Bergsland, Susanna Kjellander · 2009 · BMC Neuroscience
  64. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
    Takao Yasuhara, Tetsuro Shingo, Isao Date · 2007 · PubMed
  65. Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo
    Veljko Puskovic, Darren P. Wolfe, James R. Goss, Shaohua Huang, Marina M. Mata, Joseph C. Glorioso, David J. Fink · 2004 · Molecular Therapy
  66. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease
    Jollivet, Christophe, Aubert-Pouessel, Anne, Clavreul, Anne, Venier-Julienne, Marie-Claire, Montero-Menei, Claudia N., Benoit, Jean-Pierre, Menei, Philippe · 2004 · Neuroscience Letters
  67. Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase
    Seong Su Kang, Zhourui Wu, Xia Liu, Laura E. Edgington‐Mitchell, Keqiang Ye · 2022 · Neurotherapeutics
  68. Viral Vector Mediated Overexpression of Human α-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease
    Matthew Maingay, Marina Romero‐Ramos, Deniz Kirik · 2005 · CNS Spectrums
  69. Survival and Immunogenicity of Mesenchymal Stem Cells From the Green Fluorescent Protein Transgenic Rat in the Adult Rat Brain
    Teresa C. Moloney, Peter Dockery, Anthony J. Windebank, Frank Barry, Linda Howard, Eilís Dowd · 2010 · Neurorehabilitation and neural repair
  70. Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
    Ricardo Cabezas, Marco Ávila-Rodriguez, Nelson E. Vega-Vela, Valentina Echeverrı́a, Janneth González, Oscar Hidalgo‐Lanussa, Altair Brito dos Santos, Gjumrakch M. Aliev, George Emilio Barreto · 2015 · Medicinal Chemistry
  71. Microarray Analyses Support a Role for Nurr1 in Resistance to Oxidative Stress and Neuronal Differentiation in Neural Stem Cells
    Kyle M. Sousa, Helena Mira, Anita C. Hall, Lottie Jansson-Sjöstrand, Moriaki Kusakabe, Ernest Arenas · 2006 · Stem Cells
  72. Treatment of advanced Parkinson’s disease
    Alan L. Diamond, Joseph J. Jankovic · 2006 · Expert Review of Neurotherapeutics
  73. A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice
    Kristin E. Larsen, Susanna C. Benn, İlknur Ay, Ru-Ju Chian, Samuel A. Celia, Mary P. Remington, Michelle Bejarano, Meiqin Liu, Joshua Ross, Paul Carmillo et al. · 2006 · Brain Research
  74. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases
    Richard Grondin, Zhiming Zhang, Yi Ai, Don Marshall Gash, Greg A. Gerhardt · 2003 · Birkhäuser Basel eBooks
  75. History Repeats Itself
    Philip L. Gildenberg · 2003 · Stereotactic and Functional Neurosurgery
  76. Delivery of Brain-Derived Neurotrophic Factor via Nose-to-Brain Pathway
    Siva Ram Kiran Vaka, Sathyanarayana Narasimha Murthy, Anna Balaji, Michael A. Repka · 2011 · Pharmaceutical Research
  77. α-Synuclein: A therapeutic target for Parkinson’s disease?
    Kathleen A. Maguire‐Zeiss · 2008 · Pharmacological Research
  78. Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson’s Disease
    Sina Shadfar, Yu-Gyeong Kim, Nikita Katila, Sabita Neupane, Uttam Ojha, Sunil Bhurtel, Sunil Srivastav, Gil‐Saeng Jeong, Pil‐Hoon Park, Jin Tae Hong et al. · 2016 · Molecular Neurobiology
  79. Can Growth Factors Cure Parkinson’s Disease?
    Yulia A. Sidorova, Märt Saarma · 2020 · Trends in Pharmacological Sciences
  80. Neurotrophic Factors in Neurodegenerative Disorders
    Fabio Fumagalli, Raffaella Molteni, Francesca Calabrese, Paola Francesca Maj, Giorgio Racagni, Marco Andrea Riva · 2008 · CNS Drugs
  81. A dual-hit animal model for age-related parkinsonism
    Heather A. Boger, Ann‐Charlotte Granholm, Jacqueline F. McGinty, Lawrence D. Middaugh · 2009 · Progress in Neurobiology
  82. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain
    Piotr Hadaczek, Louisa C. Johnston, John Forsayeth, Krystof S. Bankiewicz · 2010 · Neuropharmacology
  83. Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson’s disease
    Arun Kumar Mahato, Yulia A. Sidorova · 2020 · Cell and Tissue Research
  84. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment
    Aideen M. Sullivan, Gerard W. O’Keeffe · 2005 · Journal of Anatomy
  85. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients.
    Elisa Frisaldi, E. Carlino, M. Lanotte, L. Lopiano, F. Benedetti · 2014 · Cortex; a journal devoted to the study of the nervous system and behavior
  86. Delayed administration of glial cell line-derived neurotrophic factor (GDNF) protects retinal ganglion cells in a pig model of acute retinal ischemia
    Maria Voss Kyhn, Henry J. Klassen, Ulrica Englund Johansson, Karin Warfvinge, Erin Lavik, Jens Folke Kiilgaard, Jan Ulrik Prause, Erik Scherfig, Michael J. Young, Morten la Cour · 2009 · Experimental Eye Research
  87. Intracerebral Transplantation of Genetically Engineered Cells for Parkinson's Disease: Toward Clinical Application
    Takao Yasuhara, Isao Date · 2007 · Cell Transplantation
  88. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells
    Anne‐Sophie Caumont, Jean‐Noël Octave, Emmanuel Hermans · 2005 · Neuroscience Letters
  89. Convection-Enhanced Delivery of Neprilysin: A Novel Amyloid-β-Degrading Therapeutic Strategy
    Neil U. Barua, James Scott Miners, Alison S. Bienemann, Marcella J. Wyatt, Katharina Welser, Alethea B. Tabor, Helen Claire Hailes, Seth Love, Steven S. Gill · 2012 · Journal of Alzheimer s Disease
  90. Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration
    Ann D. Cohen, Michael J. Zigmond, Amanda D. Smith · 2010 · Brain Research
  91. ‘‘70th Birthday Professor Riederer’’ Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy?
    Wakako Maruyama, Makoto Naoi · 2012 · Journal of Neural Transmission
  92. Intermittent convection-enhanced delivery to the brain through a novel transcutaneous bone-anchored port
    Neil U. Barua, Max Woolley, Ali Bienemann, D.E. Johnson, Owen T. Lewis, Marcella J. Wyatt, Charlie Irving, S. O’Sullivan, G. Murray, Colin Fennelly et al. · 2013 · Journal of Neuroscience Methods
  93. Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: Results from an in vitro model system
    Brian S. McKay, Brooke A. Goodman, Torsten Falk, Scott J. Sherman · 2006 · Experimental Neurology
  94. Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting
    Carlotta Marianecci, Federica Rinaldi, Patrizia Nadia Hanieh, Luisa Di Marzio, Donatella Paolino, Maria Carafa · 2017 · Drug Design Development and Therapy
  95. Neurorestoration
    Mikko Airavaara, Merja H. Voutilainen, Yun Wang, Barry J. Hoffer · 2011 · Parkinsonism & Related Disorders
  96. Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
    Laura Serwer, Rintaro Hashizume, Tomoko Ozawa, Charles David James · 2010 · Journal of Visualized Experiments
  97. Use of growth factors for the treatment of Parkinson’s disease
    Toru Yasuda, Hideki Mochizuki · 2010 · Expert Review of Neurotherapeutics
  98. Rigorous Mathematical Modeling Techniques for Optimal Delivery of Macromolecules to the Brain
    Andreas A. Linninger, Mahadevabharath R. Somayaji, Libin Zhang, M.S. Hariharan, R. D. Penn · 2008 · IEEE Transactions on Biomedical Engineering
  99. The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?
    Francesca Cicchetti, Roger A. Barker · 2014 · Frontiers in Pharmacology
  100. Glial Cell Line–Derived Neurotrophic Factor Receptor Rearranged During Transfection Agonist Supports Dopamine Neurons In Vitro and Enhances Dopamine Release In Vivo
    Arun Kumar Mahato, Jaakko J. Kopra, Juho‐Matti Renko, Tanel Visnapuu, Ilari Korhonen, Nita Pulkkinen, Maxim M. Bespalov, Andrii Domanskyi, Eric Ronken, Petteri T. Piepponen et al. · 2019 · Movement Disorders